BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:Personalized medicine initiative at Gustave Roussy -  Professor Je
 an-Charles SORIA - Chef de Service\, Professor of Medicine and Medical Onc
 ology\, Paris University XI and cancer specialist at Institut Gustave\, Ro
 ussy.
DTSTART:20140114T120000Z
DTEND:20140114T130000Z
UID:TALK46358@talks.cam.ac.uk
CONTACT:Mala Jayasundera
DESCRIPTION:*Development of genomic analysis through a personalized medici
 ne program at Gustave Roussy*\n\nLudovic Lacroix\, Fabrice Andre\, Jean-Ch
 arles Soria\n\nThe Gustave Roussy comprehensive molecular screening progra
 m is being developed to complement our hospital’s clinical trials strate
 gy. The main molecular triage trials are shown in table 1. This whole init
 iative is supported by a variety of funding sources including: specific st
 ate grants\, collaborative programs with biotech or pharmaceutical compani
 es as well as philanthropic funding. The MSN (Melanoma\, Small cell and No
 nsmall cell lung cancer) trial was launched in 2009. It is a mono-centric 
 molecular screening trial for tumor samples (either archived or newly coll
 ected) from patients with lung cancer and melanomas [Planchard]. The SAFIR
 01 trial\, which was launched in 2011 for patients with metastatic breast 
 cancer and is now closed to recruitment\, required dedicated freshly froze
 n tumor biopsy samples. SAFIR01 was sponsored by UNICANCER\, the former Fr
 ench Federation of Cancer Centers and funded by INCa [André ASCO]. The up
 coming SAFIR02 trials will use NGS (70 genes)\, CGH and treatment arms acc
 ording to molecular screening results for patients with metastatic breast 
 and non-small cell lung cancer. MOSCATO (MOlecular Screening for Cancer Tr
 eatment Optimization)\, was launched in 2012. It is a mono-centric molecul
 ar triage trial for early phase I candidates and combines CGH array and se
 quencing of a gene panel performed on fresh tumor biopsy samples [Hollebec
 que]. The WINTHER Trial was launched in 2013. It is an international non-r
 andomized molecular triage study undertaken by the WIN consortium\, requir
 ing\ndedicated freshly frozen tumor biopsy samples and normal matched tiss
 ue used to screen for mutations\, translocations and copy number variation
 s (CNV) by NGS\, completed with RNA and microRNA exploration for tumors wi
 thout actionable drug targets [Kurzrock]. Data and design regarding all th
 ese trials will be presented.\n\n*References*\n\n*Andre F\,* Thomas Denis 
 Bachelot TD\, Campone M\, Arnedos M\, Dieras V\, Lacroix-Triki M\, Lazar V
 \, Gentien D\, Cohen P\, Goncalves P\, Lacroix L\, Chaffanet M\, Dalenc F\
 , Mathieu MC\, Bieche I\,Olschwang S\, Wang Q\, Commo F\, Jimenez M. Bonne
 foi HR Array CGH and DNA sequencing to\npersonalize targeted treatment of 
 metastatic breast cancer (MBC) patients (pts): A prospective multicentric 
 trial (SAFIR01). ASCO MEETING ABSTRACTS Jun 17\, 2013:511\n\n*Planchard D\
 ,* Rahal A\, Lacroix L\, Ngocamus M\, Auger N\, Saulnier P\, Dorfmuller P\
 , Soria JC\, Le Chevalier T\, Besse B. Upfront genomic testing for patient
 s with non-small cell lung cancer (NSCLC) receiving first-line platinum-ba
 sed regimen: preliminary result of the MSN study. Abstract 810 European Lu
 ng Cancer Conference 2012.(Geneva).\n\n*Hollebecque A\,* et al. Molecular 
 screening for cancer treatment optimization (MOSCATO 01):a prospective mol
 ecular triage trial — interim results. J. Clin. Oncol. 31\, 2512 (2013).
 \n\n*Kurzrock\, R*. & Tabernero\, J. WINTHER — WIN Therapeutics Clinical
  Trial. \n\nhttp://www.winconsortium.org (WIN Consortium\, 2012).\n
LOCATION:CRI Lecture Theatre\, Cambridge Research Institute
END:VEVENT
END:VCALENDAR